ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.65 Billion KRW | -30.32% |
| 2022 | 5.24 Billion KRW | 20.52% |
| 2021 | 4.35 Billion KRW | -26.58% |
| 2020 | 5.92 Billion KRW | -26.84% |
| 2019 | 8.1 Billion KRW | -19.07% |
| 2018 | 10.01 Billion KRW | -67.97% |
| 2017 | 31.25 Billion KRW | 9.16% |
| 2016 | 28.63 Billion KRW | -11.91% |
| 2015 | 32.5 Billion KRW | 7.85% |
| 2014 | 30.13 Billion KRW | 17.41% |
| 2013 | 25.66 Billion KRW | 9.13% |
| 2012 | 23.52 Billion KRW | 13.86% |
| 2011 | 20.65 Billion KRW | 61.91% |
| 2010 | 12.75 Billion KRW | -9.21% |
| 2009 | 14.05 Billion KRW | -18.18% |
| 2008 | 17.17 Billion KRW | 22.96% |
| 2007 | 13.96 Billion KRW | 72.21% |
| 2006 | 8.11 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 3.82 Billion KRW | 4.63% |
| 2023 Q4 | 3.65 Billion KRW | -34.5% |
| 2023 FY | 3.65 Billion KRW | -30.32% |
| 2023 Q1 | 5.65 Billion KRW | 7.81% |
| 2023 Q2 | 5.63 Billion KRW | -0.4% |
| 2023 Q3 | 5.57 Billion KRW | -0.93% |
| 2022 Q4 | 5.24 Billion KRW | -3.15% |
| 2022 Q1 | 5.5 Billion KRW | 0.0% |
| 2022 Q3 | 5.41 Billion KRW | 2.74% |
| 2022 Q2 | 5.27 Billion KRW | -4.34% |
| 2022 FY | 5.24 Billion KRW | 20.52% |
| 2021 Q2 | 8.35 Billion KRW | 13.58% |
| 2021 FY | 4.35 Billion KRW | -26.58% |
| 2021 Q1 | 7.35 Billion KRW | 24.05% |
| 2021 Q3 | 7.5 Billion KRW | -10.2% |
| 2020 Q1 | 7.05 Billion KRW | -12.98% |
| 2020 Q4 | 5.92 Billion KRW | -12.72% |
| 2020 Q3 | 6.79 Billion KRW | -12.28% |
| 2020 Q2 | 7.74 Billion KRW | 9.79% |
| 2020 FY | 5.92 Billion KRW | -26.84% |
| 2019 Q3 | 8.86 Billion KRW | 8.15% |
| 2019 Q1 | 11.37 Billion KRW | 13.64% |
| 2019 Q2 | 8.19 Billion KRW | -27.99% |
| 2019 FY | 8.1 Billion KRW | -19.07% |
| 2019 Q4 | 8.1 Billion KRW | -8.56% |
| 2018 Q3 | 28.87 Billion KRW | -14.3% |
| 2018 FY | 10.01 Billion KRW | -67.97% |
| 2018 Q4 | 10.01 Billion KRW | -65.33% |
| 2018 Q2 | 33.69 Billion KRW | 0.3% |
| 2018 Q1 | 33.59 Billion KRW | 7.48% |
| 2017 FY | 31.25 Billion KRW | 9.16% |
| 2017 Q1 | 28.27 Billion KRW | -1.26% |
| 2017 Q4 | 31.25 Billion KRW | 0.68% |
| 2017 Q2 | 29 Billion KRW | 2.59% |
| 2017 Q3 | 31.04 Billion KRW | 7.02% |
| 2016 Q2 | 34.3 Billion KRW | 1.14% |
| 2016 Q1 | 33.92 Billion KRW | 4.36% |
| 2016 Q4 | 28.63 Billion KRW | -1.22% |
| 2016 Q3 | 28.98 Billion KRW | -15.52% |
| 2016 FY | 28.63 Billion KRW | -11.91% |
| 2015 FY | 32.5 Billion KRW | 7.85% |
| 2015 Q1 | 31.84 Billion KRW | 5.64% |
| 2015 Q4 | 32.5 Billion KRW | 2.42% |
| 2015 Q2 | 32.87 Billion KRW | 3.26% |
| 2015 Q3 | 31.73 Billion KRW | -3.48% |
| 2014 FY | 30.13 Billion KRW | 17.41% |
| 2014 Q4 | 30.13 Billion KRW | 7.64% |
| 2014 Q1 | 26.8 Billion KRW | 4.44% |
| 2014 Q2 | 27.83 Billion KRW | 3.83% |
| 2014 Q3 | 28 Billion KRW | 0.59% |
| 2013 Q2 | 25.45 Billion KRW | 7.15% |
| 2013 FY | 25.66 Billion KRW | 9.13% |
| 2013 Q4 | 25.66 Billion KRW | -2.65% |
| 2013 Q3 | 26.36 Billion KRW | 3.61% |
| 2013 Q1 | 23.75 Billion KRW | 0.99% |
| 2012 FY | 23.52 Billion KRW | 13.86% |
| 2012 Q4 | 23.52 Billion KRW | 0.0% |
| 2011 FY | 20.65 Billion KRW | 61.91% |
| 2011 Q3 | 7.28 Billion KRW | 3.75% |
| 2011 Q2 | 7.02 Billion KRW | 582.68% |
| 2011 Q1 | 1.02 Billion KRW | 0.0% |
| 2010 Q2 | 7.03 Billion KRW | -6.4% |
| 2010 Q3 | 6.41 Billion KRW | -8.76% |
| 2010 FY | 12.75 Billion KRW | -9.21% |
| 2010 Q1 | 7.51 Billion KRW | 0.0% |
| 2009 Q2 | 6.7 Billion KRW | 9.07% |
| 2009 FY | 14.05 Billion KRW | -18.18% |
| 2009 Q3 | 6.84 Billion KRW | 2.05% |
| 2009 Q1 | 6.15 Billion KRW | 0.0% |
| 2008 Q2 | 4.84 Billion KRW | 17.01% |
| 2008 FY | 17.17 Billion KRW | 22.96% |
| 2008 Q3 | 5.17 Billion KRW | 6.65% |
| 2008 Q1 | 4.14 Billion KRW | 0.0% |
| 2007 Q2 | 3.07 Billion KRW | 11.43% |
| 2007 Q1 | 2.75 Billion KRW | 0.0% |
| 2007 Q3 | 3.21 Billion KRW | 4.47% |
| 2007 FY | 13.96 Billion KRW | 72.21% |
| 2006 FY | 8.11 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Green Cross Holdings Corporation | 579.72 Billion KRW | 99.37% |
| Green Cross Holdings Corporation | 516.24 Billion KRW | 99.292% |
| Pharmicell Co., Ltd. | 20.87 Billion KRW | 82.492% |
| Green Cross Corporation | 516.24 Billion KRW | 99.292% |
| GeneOne Life Science, Inc. | 14.89 Billion KRW | 75.469% |
| Celltrion, Inc. | 3041.45 Billion KRW | 99.88% |
| Samsung Biologics Co.,Ltd. | 2641.36 Billion KRW | 99.862% |
| SK bioscience Co.,Ltd. | 80.64 Billion KRW | 95.469% |
| SK Biopharmaceuticals Co., Ltd. | 102.52 Billion KRW | 96.436% |
| Prestige BioPharma Limited | 18.1 Billion KRW | 79.813% |